MGX · NASDAQ · Biotechnology

Metagenomi Therapeutics (MGX)

Develops genetic medicines from microbial genome-editing systems.

$1.17
At close0.00 (0.00%)

Something off on this page? Send us feedback.

Next report
Nov 10, 2026
estimated · in 68 days
EPS estimate
−$0.64
Revenue estimate
$2.6M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.68−$0.54−$0.55−$0.60−$0.61−$0.73−$0.73Pending
Estimate−$0.62−$0.68−$0.60−$0.58−$0.60−$0.55−$0.55−$0.64
Surprise−9.7%+20.6%+8.3%−3.4%−1.7%−32.0%−32.0%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$4.1M$8.5M$8.7M$3.9M$1.2M−$257.0KPending
Estimate$8.3M$7.9M$7.8M$7.3M$5.9M$3.0M$3.0M$2.6M
Surprise−50.3%+7.2%+10.7%−46.6%−78.9%−108.5%

History

DateEstimateReportedSurprise
Nov 2026−$0.64
Aug 2026−$0.55−$0.73−32.0%
Aug 2026−$0.55−$0.73−32.0%
May 2026−$0.60−$0.61−1.7%
Mar 2026−$0.58−$0.60−3.4%

The latest year is open to everyone — the 15 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 10, 2026−$0.64$2.6M
Aug 11, 2026−$0.55−$0.73−32.0%$3.0M+0.8%
Aug 10, 2026−$0.55−$0.73−32.0%$3.0M−$257.0K−108.5%−1.6%
May 11, 2026−$0.60−$0.61−1.7%$5.9M$1.2M−78.9%0.0%
Mar 5, 2026−$0.58−$0.60−3.4%$7.3M$3.9M−46.6%−8.1%

The latest year is open to everyone — the 15 quarters behind it read with an account.

Sign in
Nov 11, 2025
Aug 12, 2025
May 13, 2025
Mar 17, 2025
Nov 13, 2024
Aug 14, 2024
May 14, 2024
Feb 10, 2024
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 29, 2022
Jun 30, 2022
Mar 31, 2022